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Abstract 
Review on GALNT6, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: GALNAC-T6, GalNAcT6 
HGNC (Hugo): GALNT6 
Location: 12q13.13 
DNA/RNA 
Note 
GALNT6 is highly expressed in many types of cancer, 
but expression of GALNT6 is hardly detectable in 
human normal tissues (Park et al., 2010). 
Description 
Human GALNT6 gene is located on 12  
chromosome at q13.13 location. The GALNT6 gene is 
composed of 12 exons and ORF (open reading frame) 
is 1869 bp. 
Protein 
Note 
Human GALNT6 gene encodes 622 amino acids of 
71159 Da.  
The protein is involved in the first step of O-type 
glycosylation by transferring UDP-GalNAc to Ser/Thr 
site of substrate protein. GALNT6 was firstly identified 
as a glycosyltransferase with high sequence similarity 
to GALNT3 (Bennett et al., 1999).  
GALNT6 has similar kinetic properties with other 
GALNTs but preferentially glycosylated fibronectin 
peptide in vitro. Because of expression in WI38 
fibroblast cells, GALNT6 was regarded as a candidate 
for synthesis of the oncofetal fibronectin (Bennett et al., 
1999). GALNT6 has two possible N-type glycosylation 
sites at N476 and N611. 
 
Functional domain of GALNT6. The protein contains signal peptide (1-34 aa), Gal/GalNAc transferase motif (180-370 aa), and 
ricin/lectin-like domain (496-622 aa). 
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Description 
The mucin-type O-glycosylation is initiated by GALNT 
family members that transfer N-acetyl-alpha-D-
galactosamine (GalNAc) to serine or threonine residues 
on the target protein (Ten Hagen et al., 2003). This 
modification occurs in the Golgi complex and is 
presumably controlled by the expressions and 
distributions of GALNT proteins (Brooks et al., 2007). 
Interestingly, structural alterations of these glycan 
chains are often detected in cancer cells, especially in 
breast cancer. For instances, the O-glycans were often 
truncated (core 1-based type) in breast carcinoma cells, 
whereas they were extended its chain (core 2-based 
type) in normal breast cells (Burchell et al., 2001). O-
type glycosylation is one of common modifications that 
have multiple functions related to the folding, stability, 
and targeting of various glycoproteins (Carraway et al., 
2007). Accumulating evidences have suggested that the 
GALNT family members are involved in several 
cellular functions by catalyzing substrates specific to 
each member. For instances, glycosylation by 
GALNT3 prevents proteolytic processing of FGF23 
(fibroblast growth factor 23) and that by GALNT14 
promotes ligand-stimulated clustering of death 
receptors (Wagner et al., 2007; Ichikawa et al., 2009). 
Expression 
GALNT6 is highly expressed in many types of cancer 
including breast, gastric, kidney, oral, and pancreatic 
cancer (Berois et al., 2006; Gomes et al., 2009; Kitada 
et al., 2013; Wandall et al., 2007; Li et al., 2011). 
However, in human normal tissues, GALNT6 is merely 
expressed in normal tissues and vital organs including 
lung, heart, liver, and kidney (Park et al., 2010). A 
specific expression of GALNT6 was also reported in 
the nonkeratinized epithelium of ocular cicatricial 
pemphigoid (OCP) patients (Argüeso et al., 2003). 
Localisation 
Similarly to other isoforms in the GALNT family, 
GALNT6 is localized in the Golgi complex as shown 
by double immunofluorescence staining with anti-
GALNT6 mAb and anti-Golgi-58k mAb (Park et al., 
2010). 
Function 
GALNT6 is involved in the first step of O-type 
glycosylation, and thereby may influence on folding, 
stability, and subcellular localization of target proteins. 
GALNT6 was reported to stabilize MUC1 protein 
throughout O-glycosylation and subsequently the 
accumulated MUC1 protein promoted breast cancer 
cell proliferation and induced anti-adhesive effects 
(Park et al., 2010). By O-glycosylation of fibronectin 
protein, GALNT6 showed transformational potentials 
through disruptive acinar morphogenesis and cellular 
changes similar to EMT (epithelial-to-mesenchymal  
 
transition) in normal mammary epithelial cell (Park et 
al., 2011).  
The GALNT6-mediated O-glycosylation of fibronectin 
was also reported in the TGF-β-induced EMT process 
in human prostate cells (Freire-de-Lima et al., 2011). 
Homology 
GALNT6 has 30~63% of amino acid homology with 
other family members, with the highest homology to 
GALNT3 (63%). In crystal structure analysis of murine 
GALNT isoforms, GALNT1 was reported to be more 
similar to GALNT6 according to the electrostatic 
surface potential models (Fritz et al., 2004). 
Implicated in 
Breast cancer 
Note 
High expression of GALNT6 was frequently observed 
in human breast cancers (Berois et al., 2006; Freire et 
al., 2006; Patani et al., 2008; Park et al., 2010). In 
particular, strong expression of GALNT6 was reported 
in most of DCIS (ductal carcinoma in situ) indicating 
that GALNT6 should play important roles in early 
human breast carcinogenesis (Berois et al., 2006).  
On the other hand, a study of metastatic breast cancer 
showed that GALNT6 expression was frequently 
detected in bone marrow biopsy samples and therefore 
suggested that GALNT6 would be a good target for 
detection of disseminated breast cancer cells (Freire et 
al., 2006). 
Prognosis 
Disease free survival was elongated in breast cancer 
patients who showed negative expression of GALNT6 
from bone marrow biopsy (Freire et al., 2006). 
Gastric cancer 
Note 
High expression of GALNT6 was reported in human 
gastric cancers. A heterogeneous expression and 
staining pattern of GALNT6 was observed in 79% of 
gastric carcinomas, and its expression level was 
associated with the presence of venous invasion 
(Gomes et al., 2009). 
Oral cancer 
Note 
GALNT6 was expressed in the oral squamous 
carcinoma cells, but not expressed in normal stromal 
fibroblasts (Wandall et al., 2007). 
Pancreatic cancer 
Note 
GALNT6 was highly expressed in pancreatic cancer, 
but not expressed in normal ductal epithelium. A close 
relationship was noted between GALNT6-positive 
expression and pathological well/moderate 
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differentiated type, small tumor size, and absence of 
vascular invasion (Li et al., 2011). 
Prognosis 
In contrast to other reports, the outcome of the patients 
who had GALNT6-positive expression was 
significantly better than that with GALNT6-negative 
expression, especially in the early period after surgery 
(Li et al., 2011). 
Renal cell carcinoma 
Note 
GALNT6 was weakly expressed in 64 out of 254 renal 
cell carcinomas (Kitada et al., 2013). 
Prognosis 
GALNT6-positive patients showed poor prognosis with 
lower disease-specific survival rate (Kitada et al., 
2013). 
Ocular cicatricial pemphigoid (OCP) 
Note 
OCP is one of the subsets of mucous membrane 
pemphigoid, which may be caused by aberrant 
synthesis of mucin O-glycans and thus by alteration of 
the physicochemical properties of mucins. GALNT6 
was expressed in the apical stratified epithelia, but 
specific expression of GALNT6 was detected in 
nonkeratinized epithelium of OCP patients, without 
expression in keratinized epithelium nor normal 
subjects (Argüeso et al., 2003). 
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